EP4090174A1 - Formulation nutraceutique - Google Patents

Formulation nutraceutique

Info

Publication number
EP4090174A1
EP4090174A1 EP21730452.6A EP21730452A EP4090174A1 EP 4090174 A1 EP4090174 A1 EP 4090174A1 EP 21730452 A EP21730452 A EP 21730452A EP 4090174 A1 EP4090174 A1 EP 4090174A1
Authority
EP
European Patent Office
Prior art keywords
choline
nutraceutical formulation
formulation
weight per
phosphatidylcholine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21730452.6A
Other languages
German (de)
English (en)
Inventor
designation of the inventor has not yet been filed The
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stellar Biomolecular Research GmbH
Original Assignee
Stellar Biomolecular Research GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stellar Biomolecular Research GmbH filed Critical Stellar Biomolecular Research GmbH
Publication of EP4090174A1 publication Critical patent/EP4090174A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention generally relates to a nutraceutical formulation.
  • the present invention describes a nutraceutical formulation comprising three types of choline containing molecules for supporting healthy cell membrane, cognitive functions, lipid transport and reduction of plasmatic homocysteine.
  • Choline is a nutrient obtained through both dietary intake and endogenous synthesis. Our body needs choline to synthesize phosphatidylcholine and sphingomyelin, two major phospholipids vital for cell membranes.
  • Phosphatidylcholine (PC) is a molecule that contains two fatty acids attached to a glycerol backbone with a phosphate group and choline. All plant and animal cells need choline to preserve their structural integrity.
  • choline is needed to produce acetylcholine, an important neurotransmitter for memory, mood, muscle control and other brain and nervous systems functions.
  • choline is initially converted to phosphocholine before being converted into cytidine diphosphate-choline (CDP choline).
  • CDP choline cytidine diphosphate-choline
  • the conversion of phosphocholine to CDP choline is the slowest step in the choline metabolism chain.
  • CDP choline is the choline form produced after the rate-limiting step and has the ability to cross blood-brain barrier and reach the central nervous system.
  • Choline alfoscerate (Alpha GPC) are obtained in the body by the decomposition of phosphatidylcholine. Enzyme reactions in choline pathways are bidirectional, hence fortification of Alpha GPC allows phosphatidylcholine to be used for other purpose instead of broken down into choline. Alpha GPC enters choline pool at different point in choline pathways and also have the ability to cross blood-brain barrier and reach central nervous system.
  • the present invention suggests a nutraceutical formulation which acts as a dietary supplement to increase bioavailability of free choline that is essential for the synthesis of neurotransmitter acethylcholine and supports healthy cell membrane, cognitive functions, lipid transport and reduction of plasmatic homocysteine.
  • An embodiment of the present invention provides a nutraceutical formulation, comprising phosphatidylcholine, cytidine diphosphate-choline, and choline alfoscerate, characterized in that, combination of the phosphatidycholine with cytidine diphosphate-choline and choline alfoscerate having synergistic effect in increasing choline bioavailability for supporting cognitive functions and cellular health.
  • the formulation further comprises alpha tocopherol.
  • the phosphatidylcholine weight per intake is 100-1000mg.
  • the cytidine diphosphate-choline weight per intake is 50-250mg.
  • the choline alfoscerate weight per intake is 50-600mg.
  • the alpha tocopherol weight per intake is 10-30mg.
  • a nutraceutical formulation comprising phosphatidylcholine, cytidine diphosphate-choline and choline alfoscerate, for the treatment of disease or condition related to the aggregation of b-amyloid, Alzheimer’s disease, stroke, to improve blood-brain barrier function, to improve blood-brain barrier transport of an active agent across the blood-brain barrier, to improve or maintain cognitive health, to provide neuro protection, to facilitate neural development or to facilitate cerebral metabolism, such that one or more of the conditions are treated, improved or facilitated.
  • the formulation further comprises alpha tocopherol.
  • the phosphatidylcholine weight per intake is 100-1000mg.
  • the cytidine diphosphate-choline weight per intake is 50-250mg.
  • the choline alfoscerate weight per intake is 50-600mg.
  • the alpha tocopherol weight per intake is 10-30mg.
  • the present invention generally relates to a nutraceutical formulation.
  • the present invention describes a nutraceutical formulation which consists of three types of choline containing molecules for supporting healthy cell membrane, cognitive functions, lipid transport and reduction of plasmatic homocysteine.
  • the present invention discloses nutraceutical formulation which comprises a combination of three main active ingredients which are three types of choline- containing molecules such as choline alfoscerate (Alpha GPC), cytidine diphosphate-choline (CDP Choline), and phosphatidylcholine along with alpha tocopherol.
  • Choline is a nutrient obtained through both dietary intake and endogenous synthesis, and it is used for the synthesis of the neurotransmitter acethycholine and also involved in methyl-group metabolism, particularly in the liver, because it is a major dietary source of methyl groups via its irreversible oxidation to betaine and the subsequent synthesis of S-adenosylmethionine.
  • Liver is the major site of choline metabolism, where it is found primarily as phosphatidylcholine, it is important for the maintenance of phosphatidylcholine supply within the liver.
  • choline is initially converted to phosphocholine by choline kinase (CK), using ATP as a phosphate donor.
  • An enzyme called phosphocholine cytidylyltransferase (CCT) uses cytidine triphosphate (CTP) to convert phosphocholine into CDP choline.
  • CTP cytidine triphosphate
  • the conversion of phosphocholine to CDP choline is the slowest step in the choline metabolism chain.
  • CDP choline is included in the formulation of the present invention because it is the choline form produced after the rate-limiting step and has the ability to cross the blood-brain barrier and reach the central nervous system.
  • CDP choline is more than a choline source; it contains equimolar amounts of choline and cytidine which will help to increase the plasma uridine nucleotides and choline in the body.
  • Nucleotide uridine is a key factor in synaptic strength and neural connectivity.
  • CDP choline serves as a precursor to nucleotide uridine and nootropic ingredients. Uridine, along with CDP choline, promotes the growth of new dopamine receptors in the brain by activating D1 and D2 receptor signaling.
  • CDP choline is esterified withy diacylglycerol (DAG) by cholinephosphotransferase (CEPT) to produce phosphatidylcholine.
  • DAG diacylglycerol
  • CEPT cholinephosphotransferase
  • Essential fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are involved in the creation of DAG.
  • Phosphatidylcholine is the end product of the CDP choline pathway, most choline in the body and brain are in the form of phosphatidylcholine, it serves as a reservoir for choline.
  • Phosphatidylcholine involves in the hepatic transport of VLDL (very low density lipoproteins) and maintenance of the cell membrane integrity that is vital to all the basic biological processes. Phosphatidylcholine also serve as an excellent emulsifier that help to enhance the bioavailability of nutrients (in this case alpha GPC, CDP choline and alpha tocopherol) with which it is co-administered.
  • VLDL very low density lipoproteins
  • Alpha GPC are obtained in the body by the decomposition of phosphatidylcholine. Enzyme reactions in choline pathways is bidirectional, fortification of Alpha GPC in the formulation allow phosphatidylcholine to be used for other purpose instead of broken down into choline.
  • Alpha GPC enter choline pool at different point in choline pathways and also have the ability to cross the blood-brain barrier and reach central nervous system.
  • Alpha GPC serves as a potent nootropic ingredient and for sustenance of choline uptake by an aging brain.
  • Alpha GPC has distinct roles besides the ability to cross blood-brain barrier to directly increase the acetylcholine level within the central nervous system.
  • Alpha GPC also serves as a precursor for biosynthesis of neuronal cell phospholipids, and further augments choline pool to produce betaine which function is to reduce homocysteine level in the blood.
  • the different kinetics and interaction with choline pathways, the fortification of Alpha GPC and CDP Choline in the formulation will allow the upregulation of the CDP Choline pathways and turnover of the phosphatidylcholine cycle; which then allow phosphatidylcholine to be utilised lipid transport, formation of phosphatidylserine, sphingomyelin, and support cellular membrane structure and functions rather than breakdown to augment the choline pool, and also offer higher availability of choline for acetylcholine synthesis and other metabolic functions.
  • the formulation also comprises an active form of fat-soluble antioxidants such as alpha tocopherol.
  • Alpha tocopherol major biological role is protecting polyunsaturated fats and other components of the cell membrane from reactive oxygen species and free radicals.
  • Alpha tocopherol plays various role in supporting neurologic functions, cardiovascular health, and liver, primarily by protecting the cells from damage associated with oxidative stress. It has been found that alpha tocopherol promote healthy brain ageing, delay Alzheimer’s disease related functional decline, increase the oxidative resistance in vitro, prevent atherosclerotic plaque formation and prevent liver fibrosis driven by oxidative damage.
  • Alpha tocopherol serves as antioxidant that protects cell membranes, proteins, and DNA from oxidation and thereby contributes to cellular health.
  • Alpha tocopherol provides stability to the composition against lipid oxidation and limit the conversion of choline to trimethylamine (TMA) and trimethylamine n-oxide (TMAO) and this will prolong the product quality and reduce the risk of adverse effect caused by high concentration of choline. Bioavailability of alpha tocopherol also increases with the presence of phospholipid.
  • Each ingredient has synergistic actions and standalone actions to support the structural integrity of cell membranes, methyl metabolism, cholinergic neurotransmission, transmembrane signalling, and lipid and cholesterol transport and metabolism.
  • the general adequate intake of choline for adults is 530mg per day for males, 425mg per day for females, and the daily upper limit is 3500mg per day.
  • a nutraceutical formulation of the present invention contains the following: a. Phosphatidylcholine providing 13.7% choline by weight. b. CDP Choline providing 21.4% choline by weight. c. Alpha GPC providing 40.3% choline by weight.
  • a randomized controlled trial with supplementation of Alpha GPC at 400mg, three times daily, divided dosage for three months shows cognitive and functional improvement in the treated group versus placebo (De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003 Jan;25(1):178-93. doi: 10.1016/s0149-2918(03)90023-3. PMID: 12637119).
  • the choline containing composition is also specifically formulated for lipid metabolism, reduction of free fatty acid build-up at site of stroke induced nerve damage, to dissolve blood clots, conditions related to aggregation of b-amyloid, and Alzheimer’s disease.
  • the preferred method of administration is oral to allow the formulation to be consumed in divided dosages with dosing interval.
  • compositions of the invention can be formulated with suitable carriers such as starch, sucrose, or lactose in tablets, capsules, solutions, syrups and emulsions.
  • suitable carriers such as starch, sucrose, or lactose in tablets, capsules, solutions, syrups and emulsions.
  • the tablet or capsule of the present invention can be coated with an enteric coating that dissolves at a pH of about 6.0 - 7.0.
  • Formulation of the compositions of the invention into a soft gel capsule can be accomplished by many methods known in the art. Often the formulation will include an acceptable carrier, such as an oil, or other suspending or emulsifying agent.
  • an acceptable carrier such as an oil, or other suspending or emulsifying agent.
  • Suitable optional carriers include but are not limited to, for example, fatty acids, esters and salts thereof, that can be derived from any source, including, without limitation, natural or synthetic oils, fats, waxes or combinations thereof. Moreover, the fatty acids can be derived, without limitation, from non-hydrogenated oils, partially hydrogenated oils, fully hydrogenated oils or combinations thereof.
  • Non limiting exemplary sources of fatty acids include seed oil, fish or marine oil, canola oil, vegetable oil, safflower oil, sunflower oil, nasturtium seed oil, mustard seed oil, olive oil, sesame oil, soybean oil, corn oil, peanut oil, cottonseed oil, rice bran oil, babassu nut oil, palm oil, low erucic rapeseed oil, palm kernel oil, lupin oil, coconut oil, flaxseed oil, evening primrose oil, jojoba, wheat germ oil, tallow, beef tallow, butter, chicken fat, lard, dairy butterfat, shea butter or combinations thereof.
  • Specific non-limiting exemplary fish or marine oil sources include shellfish oil, tuna oil, mackerel oil, salmon oil, menhaden, anchovy, herring, trout, sardines or combinations thereof.
  • the source of the fatty acids is fish or marine oil (DHA or EPA), soybean oil or flaxseed oil.
  • beeswax can be used as a suitable carrier, as well as suspending agents such as silica (silicon dioxide).
  • the compositions of the invention can further include various ingredients to help stabilize, or help promote the bioavailability of the components of the beneficial compositions of the invention or serve as additional nutrients to an individual's diet. Suitable additives can include vitamins and biologically-acceptable minerals.
  • Non-limiting examples of vitamins include vitamin A, B vitamins, vitamin C, vitamin D, vitamin K and folic acid.
  • Non-limiting examples of minerals include iron, calcium, magnesium, potassium, copper, chromium, zinc, molybdenum, iodine, boron, selenium, manganese, derivatives thereof or combinations thereof. These vitamins and minerals can be from any source or combination of sources, without limitation.
  • Non-limiting exemplary B vitamins include, without limitation, thiamine, niacinamide, pyridoxine, riboflavin, cyanocobalamin, biotin, pantothenic acid or combinations thereof.
  • compositions comprising the compositions of the invention can be manufactured by methods of conventional mixing, dissolving, granulating, dragee-making levigating, emulsifying, encapsulating, entrapping or lyophilization processes.
  • the compositions can be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries that facilitate processing of the compositions into preparations that can be used.
  • antioxidant refers to synthetic or natural substances that prevent or delay the oxidative deterioration of a compound.
  • exemplary antioxidants include tocopherols, flavonoids, catechins, superoxide dismutase, lecithin, gamma oryzanol; vitamins, such as vitamins A, C (ascorbic acid) and beta-carotene; natural components such as camosol, camosic acid and rosmanol found in rosemary and hawthorn extract, proanthocyanidins such as those found in grapeseed or pine bark extract, and green tea extract.
  • compositions of the invention can take the form of, for example, lozenges, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate).
  • binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrants e.
  • Preparations for oral administration can be suitably formulated to give controlled release of the composition as is well known.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation nutraceutique comprenant de la phosphatidylcholine, la cytidine diphosphate-choline et l'alfoscerate de choline, caractérisée en ce que, la combinaison de la phosphatidylcholine avec de la cytidine diphosphate-choline et de l'alfoscerate de choline a un effet synergique en augmentant la biodisponibilité de la choline pour supporter des fonctions cognitives et la santé cellulaire.
EP21730452.6A 2021-04-06 2021-06-03 Formulation nutraceutique Pending EP4090174A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2021001876 2021-04-06
PCT/IB2021/054853 WO2022214861A1 (fr) 2021-04-06 2021-06-03 Formulation nutraceutique

Publications (1)

Publication Number Publication Date
EP4090174A1 true EP4090174A1 (fr) 2022-11-23

Family

ID=76532228

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21730452.6A Pending EP4090174A1 (fr) 2021-04-06 2021-06-03 Formulation nutraceutique

Country Status (3)

Country Link
EP (1) EP4090174A1 (fr)
CN (1) CN115443074A (fr)
WO (1) WO2022214861A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8017657B1 (en) * 2001-09-07 2011-09-13 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
US20110008495A1 (en) * 2009-07-09 2011-01-13 Nawgan Products, Llc Liquid dietary supplement composition
WO2018060396A1 (fr) * 2016-09-29 2018-04-05 Nestec S.A. Acides gras oméga-3 et choline utilisés en tant que neuroprotecteurs chez des patients non atteints de démence

Also Published As

Publication number Publication date
WO2022214861A1 (fr) 2022-10-13
CN115443074A (zh) 2022-12-06

Similar Documents

Publication Publication Date Title
Stoll et al. Omega-3 fatty acids and bipolar disorder: a review
EP0347056B1 (fr) Compositions d'acides gras essentiels
AU2011260037B2 (en) Dietary formulations
Freeman Omega-3 fatty acids in major depressive disorder.
KR20140022888A (ko) 영양 조성물
JP2007526303A (ja) 可溶化ｃｏｑ−１０およびカルニチン
US6852870B2 (en) Omega-3 fatty acids in the treatment of depression
US20150025133A1 (en) Nutritional compositions including rrr-alpha tocopherol and polyunsaturated fatty acids
JPWO2005023021A1 (ja) ダイエット食品
US10702496B2 (en) Method of using a composition for enhancing newborn infant cognitive, brain and/or CNS development
US20070122452A1 (en) Fat composition
US20160279095A1 (en) Use of nutritional compositions including natural vitamin e, and polyunsaturated fatty acid
TW201735801A (zh) 包含β-羥基-β-丁酸甲酯之營養產品
WO2015115885A1 (fr) Procédé pour réduire les lésions de la substance blanche, les hyperintensités de la substance blanche (wmh), la leucoaraiose ou la maladie de la substance blanche périventriculaire chez des personnes âgées
Park et al. Gamma-linolenic acid egg production enriched with hemp seed oil and evening primrose oil in diet of laying hens
EP4090174A1 (fr) Formulation nutraceutique
WO2004056370A1 (fr) Utilisation d'une composition a base d'acides gras pour le traitement de la sterilite masculine
JPH04504257A (ja) 非経口栄養摂取用医薬脂質組成物
US11752121B2 (en) SmartCore compositions and methods
CN115104731A (zh) 营养组合物以及包含所述营养组合物的食品
JP2002363095A (ja) 血圧上昇抑制剤
WO2017069631A1 (fr) Procédé pour améliorer l'équilibrioception chez des individus sains, et composition nutritionnelle
IE20110260U1 (en) Dietary formulations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210701

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WONG, BI FAH

Inventor name: TAN, KOR SENG CHAN KOK SENG

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)